We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.07 | -0.50% | 13.98 | 12,751 | 13:14:05 |
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier today. Shareholders voted to approve the elections of Murray Goldberg, Roberto Mignone, Dr. Perry Nisen and Nechemia (Chemi) Peres to the Company’s Board of Directors.
"We greatly appreciate the support of Teva's shareholders as we work to strengthen the leadership of Teva, with the addition of these distinguished Board members, and our ongoing search to find the best chief executive officer to lead Teva,” stated Dr. Sol Barer, Chairman of the Board. “We continue to make changes to enhance our Board of Directors; address matters that are important to our shareholders, and continue to look for opportunities to make a difference to patients and healthcare systems around the world.”
Dr. Barer continued, “We are pleased to have added these world class directors to our Board from both Israel and around the world. Teva has become a global company by putting innovation front and center and never shying away from change. Teva’s new directors share our conviction that innovation is at the heart of Teva's strategy and of all our businesses – a conviction with clear roots in Israel. The primary task for our new leadership, which will include a new CEO, will be to best position Teva to handle today's challenges and prepare the Company for the emerging pharma landscape. I would like to take this opportunity to thank our outgoing directors, Ory Slonim and Roger Abravanel, who are leaving us today, and Yossi Nitzani, who is leaving in September, for their wisdom and dedication to Teva.”
Four New Independent Directors Join the Teva Board
Murray Goldberg, the former Chief Financial Officer and Senior Vice President of Administration of Regeneron Pharmaceuticals, who brings extensive financial and operational experience at leading global pharmaceutical companies.
Roberto Mignone, the founder and managing partner of Bridger Management LLC, where he oversees the management of approximately $1 billion invested in publicly traded healthcare companies.
Dr. Perry Nisen, who brings two decades of experience in a variety of senior roles in pharmaceutical research and development at non-profits and global pharmaceutical companies like GlaxoSmithKline and Abbott Laboratories and is currently the Chief Executive Officer and Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute.
Chemi Peres, the managing general partner and co-founder of Pitango Venture Capital, who oversees a diverse investment portfolio spanning health care to IT.
Results from the 2017 Annual Meeting of Shareholders
All proposals were approved by the required majority of shareholders, by the following percentages of shares voting:
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
View source version on businesswire.com: http://www.businesswire.com/news/home/20170713005818/en/
Teva Pharmaceutical Industries Ltd.IR Contacts:United StatesKevin C. Mannix, 215-591-8912Ran Meir, 215-591-3033orIsraelTomer Amitai, 972 (3) 926-7656orPR Contacts:IsraelIris Beck Codner, 972 (3) 926-7687orUnited StatesDenise Bradley, 215-591-8974
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions